Osteoporosis News

The FDA expanded the indication for the monoclonal antibody denosumab to include the treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture, according to a press release from Amgen.

Approximately 15% of patients with osteoporosis who stop taking bisphosphonates experience bone fractures, according to study results published in Endocrine Practice.

Researchers from the Hospital for Special Surgery are currently enrolling patients for a 2-year pilot study to determine the effects of secukinumab on the skeleton among men and women with ankylosing spondylitis, according to a press release.

Every 2 minutes, someone in the United States breaks their hip, and if that fracture is related to osteoporosis, the likelihood that person will experience another fracture jumps three to five times, according to the National Bone Health Alliance.

In women aged at least 80 years with osteoporosis, bone mineral density at the total hip, femoral neck and lumbar spine increased during 18 months with abaloparatide therapy compared with placebo, according to findings from the ACTIVE trial.

The FDA has rejected Amneal Pharmaceuticals’ citizen petition to refrain from approving any abbreviated new drug applications for generic versions of teriparatide as treatment for osteoporosis.

Screening for fracture risk led to a statistically significant reduction in hip fractures among older women, according to data published in The Lancet.

Although the effects of depression on OA knee pain do not change over time, depression persistence can significantly increase the severity of that pain, according to findings published in Arthritis Care and Research.

Adults, particularly those with a low income and aged at least 65 years, have an increased risk for bone fracture and osteoporosis-related loss of bone mineral density with long-term exposure to air pollution, according to findings published in The Lancet Planetary Health.

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Robin K. Dore, MD, spoke about results of the ACTIVExtend trial of postmenopausal women with osteoporosis. She said results showed that women who received abaloparatide for 18 months followed by 24 months of alendronate had a sustained decrease of vertebral and nonvertebral fractures compared to women who received placebo followed by alendronate.